Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations

This is first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer. DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, …

rad001
clear cell renal cell carcinoma
mtor inhibitor
carcinoma
vegf
  • 16 views
  • 24 Oct, 2022
  • 10 locations
Magnesium Sulfate Versus Dexmedetomidine on Anesthesia Awakening.

pheochromocytoma). Despite these advantages in the use of these important adjuncts, there is a concern about the quality and awakening time of the patients who use them. The purpose of this trial is to compare the

Accepts healthy volunteers
  • 0 views
  • 11 Nov, 2021
  • 1 location
Multicenter Pheochromocytoma and Paraganglioma Evaluation

Target population: Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility

adrenal pheochromocytoma
special care
pheochromocytoma
paraganglioma
  • 36 views
  • 24 Jan, 2021
  • 1 location
Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma

The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often

adrenal pheochromocytoma
18f-fdopa
somatostatin
dotatate
ct scan
  • 20 views
  • 28 Oct, 2022
  • 1 location
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Pheochromocytoma/Paraganglioma.

adrenal pheochromocytoma
pheochromocytoma, malignant
stage iv adrenocortical cancer
malignant pheochromocytoma
paraganglioma
  • 14 views
  • 17 Dec, 2021
  • 13 locations
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)

This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible …

somatostatin
dotatate
metastatic disease
  • 0 views
  • 18 Oct, 2022
  • 13 locations
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors

This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET) or von

  • 0 views
  • 20 Oct, 2022
  • 41 locations
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) Pheochromocytoma

squamous cell carcinoma of the head and neck
hydrocortisone
immunosuppressive agents
squamous cell carcinoma
immunosuppression
  • 6651 views
  • 22 Oct, 2022
  • 752 locations
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) (LIBRETTO-001)

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

kidney function test
systemic therapy
cfdna
solid tumour
ret inhibitor
  • 1279 views
  • 22 Oct, 2022
  • 86 locations
Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Background People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect them. This may help …

neuroendocrine tumor
cyst
genetic testing
pet/ct scan
dotatate
  • 0 views
  • 28 Oct, 2022
  • 1 location